Commercial A year after Vertex’s big launch, pain drug research faces a pivotal moment BioPharma DiveJournavx revived an area of development long considered a graveyard.Pain & AnaesthesiaRead full story pharminent May 12, 2026 (Last updated: May 16, 2026) BioPharma Dive Journavx revived an area of development long considered a graveyard. Pain & Anaesthesia Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA weighs drug repurposing pathway for underserved diseasesNext: Novo says high-dose Wegovy can cause 28% weight loss Related Stories Commercial Post-marketing oncology studies: Enabling faster recruitment and lower costs pharminent June 22, 2026 Commercial The first 14 days: How specialty programs set patients up for success pharminent June 22, 2026 Commercial Denali sells FDA voucher for $195M to support neurodegenerative pipeline pharminent June 19, 2026
